Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-(2-hydroxy-cyclopentyl)-7-oxo-heptanamidine is a synthetic small molecule compound with the molecular formula C12H22N2O2 and a molecular weight of approximately 226.32 g/mol[5][3][9]. It belongs to the class of cyclopentanols and is characterized by three defined stereocenters[5]. The compound has been studied as an experimental agent and is not approved for clinical use in any country[6]. Its primary mechanism of action is reported as inhibition of prothrombin (thrombin precursor), suggesting potential anticoagulant or antithrombotic activity[6]. No approved indications or marketed formulations are known.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-(2-hydroxy-cyclopentyl)-7-oxo-heptanamidine.